Hemangiopericytomas are highly aggressive meningeal tumors with tendencies for recurrence and metastasis. The purpose of this retrospective, singleinstitution review was to evaluate the efficacy and role of stereotactic radiosurgery in the management of recurrent hemangiopericytomas. METHODS: We reviewed data for patients who underwent stereotactic radiosurgery at the University of Pittsburgh between 1987 and 2001. Fourteen patients underwent radiosurgery for 15 discrete tumors. Prior treatments included transsphenoidal resection (n ϭ 1), craniotomy and resection (n ϭ 27), embolization (n ϭ 1), and conventional radiotherapy (n ϭ 7). Clinical and radiological responses were evaluated. Follow-up periods varied from 5 to 76 months (mean, 31.3 mo; median, 21 mo). The mean radiation dose to the tumor margin was 15 Gy. RESULTS: Seventy-nine percent of patients (11 of 14 patients) with recurrent hemangiopericytomas demonstrated local tumor control after radiosurgery. Twelve of 15 tumors (i.e., 80%) dramatically decreased in size on follow-up imaging scans. Regional intracranial recurrences were retreated with radiosurgery for two patients (i.e., 15%); neither of those two patients experienced long-term tumor control. Local recurrences occurred 12 to 75 months (median, 21 mo) after radiosurgery. Local tumor control and survival rates at 5 years after radiosurgery were 76 and 100%, respectively (Kaplan-Meier method). We could not correlate prior irradiation or tumor size with tumor control. Twenty-nine percent of the patients (4 of 14 patients) developed remote metastases. Radiosurgery did not seem to offer protection against the development of intra-or extracranial metastases. CONCLUSION: Gamma knife radiosurgery provided local tumor control for 80% of recurrent hemangiopericytomas. When residual tumor is identified after resection or radiotherapy, early radiosurgery should be considered as a feasible treatment modality. Despite local tumor control, patients are still at risk for distant metastasis. Diligent clinical and radiological follow-up monitoring is necessary.
M
eningeal hemangiopericytomas are rapidly growing, richly vascular, mesenchymal neoplasms. They account for less than 1% of all central nervous system tumors and approximately 2.4% of tumors presumed to be meningiomas (6) . Intracranial hemangiopericytoma has been linked to the meningioma family as an "angioblastic" variant, whereas others consider it a distinct entity (1) . Hemangiopericytomas have a predilection for both local and distant central nervous system recurrences and exhibit an increased tendency to metastasize, compared with nonmalignant meningiomas (1, 5) .
Because meningeal hemangiopericytomas are difficult to cure surgically, postoperative radiosurgery and radiotherapy have been proposed, even after gross total tumor resection (3, 5, 7, 9, 17) . We report our experience using radiosurgery to treat 14 patients with recurrent or newly discovered meningeal hemangiopericytomas after surgical resection.
PATIENTS AND METHODS
Between 1987 and 2001, 14 patients underwent initial radiosurgery for treatment of 15 meningeal hemangiopericytomas. Fourteen of these were residual tumors and one was a new tumor distinct from the primary tumor. All patients had undergone previous surgical resection and neuropathological confirmation of the diagnosis. The variations in the presenting symptoms (e.g., seizures, motor weakness, visual dysfunction, and cranial nerve palsies) indicate the unpredictable locations of the neoplasms in this series of cases. The locations of the 14 recurrent tumors and 1 new tumor were as follows: frontal, 5; occipital, 4; parasellar, 4; temporal, 1; parietal, 1.
Patients underwent placement of a Leksell Model G stereotactic frame (Elekta Instruments, Atlanta, GA) with local anesthesia. For most patients, contrast-enhanced, 1-mm-thick, volume acquisition, magnetic resonance imaging scans were used to define the tumor margins and facilitate dose-planning. Patients treated before 1991 underwent computed tomography-based targeting. Patients underwent gamma knife radiosurgery with either a Model U or Model B/C unit (Elekta Instruments), at the University of Pittsburgh. Whenever possible, patients underwent follow-up magnetic resonance imaging at 3-to 6-month intervals after radiosurgery, and assessments of tumor responses were made in comparison with preradiosurgical films. Local tumor control is defined here as either decreased or unchanged volume of the treated lesion on follow-up imaging scans. Patients were monitored for changes in their neurological condition and for the development of recurrent tumors or metastases. Follow-up neurological assessments were performed at our institution (when possible) or by the referring neurosurgeon. Clinical evaluations were typically performed close to the time of scheduled follow-up imaging assessments.
Ten male patients and four female patients underwent radiosurgery. One woman was initially treated for a left frontal hemangiopericytoma and underwent a second radiosurgical procedure, for treatment of a contralateral lesion, 34 months later. The age of the patients at the time of radiosurgery varied from 13 to 71 years ( Table 1) . Each patient had undergone at least one tumor resection; 10 patients had undergone two or more previous procedures, including craniotomy and resection, transsphenoidal resection, embolization, and radiotherapy. The median dose for the seven patients who had previously undergone fractionated radiotherapy was 50 Gy (cumulative dose, 30-61 Gy). The mean follow-up period was 31.3 months (range, 5-76 mo); this represents information from the latest follow-up evaluation or data up to the point of tumor recurrence after radiosurgery.
The mean margin dose for radiosurgery was 15 Gy (range, 11-20 Gy). This dose was prescribed to the 50% isodose curve for 14 tumors and to the 40% isodose curve for 1 tumor. The maximal dose to the tumors varied from 22 to 40 Gy. The mean number of isocenters per hemangiopericytoma was 6.3 (range, 2-16). The 8-mm collimator was the most frequently used to treat all hemangiopericytomas ( 
RESULTS
Thirteen of the 14 patients treated in this series remain alive, with a mean follow-up period of 31.3 months (median, 21 mo; range, 5-76 mo) ( Table 3) . Gamma knife radiosurgery yielded tumor control for 12 of 15 hemangiopericytomas. The 12 tumors that responded to radiosurgery decreased by more than 50%, compared with their pretreatment tumor sizes ( Fig. 1) (15) . In the cases of the three tumors for which initial gamma knife radiosurgery failed, the patients had previously experienced recurrences after craniotomies and conventional radiotherapy ( Table 3) . They demonstrated tumor growth between 12 and 75 months (median, 21 mo) after radiosurgery. Two of those patients exhibited decreases in tumor size shortly after the first radiosurgical procedure but later demonstrated regrowth, at 12 and 21 months after the procedure. Those two patients underwent repeat radiosurgery, in an attempt to boost the initial radiosurgical effects. However, repeat radiosurgery for those two patients was uniformly unsuccessful in achieving lasting tumor control. In fact, repeat radiosurgery for lesions for which initial radiosurgery failed offered less than 6 months of tumor control. The other patient who demonstrated recurrence, 75 months after radiosurgery, proceeded to undergo repeat radiotherapy but ultimately died 99 months after radiosurgery, as a result of tumor progression. Overall, the 5-year local tumor control and survival rates were 76 and 100%, respectively (Kaplan-Meier method). The patient for whom the primary tumor responded to radiosurgery but a contralateral brain metastasis developed 34 months after the original radiosurgical treatment exhibited a similarly favorable response of the metastasis to repeat gamma knife radiosurgery. Neither preoperative tumor size nor location was correlated with a favorable response to radiosurgery (Fisher's test, P Ͼ 0.05). In addition, there were no statistically significant differences in the maximal or margin radiation doses in cases that responded to radiosurgery versus those that did not (Student's t test, P Ͼ 0.05). The lack of statistical significance might be a limitation resulting from the small number of patients in this series or other factors (e.g., previous radiation, tumor size, location, or proximity to eloquent brain tissue) that influenced dose-planning.
Four patients (29%) developed metastatic tumors that spread regionally or systemically during the follow-up period. For three of those patients, the primary hemangiopericytomas responded to radiosurgery, as indicated by imaging results. Metastases were noted in the right frontal region, cerebellum, ribs, lungs, and thoracic spine. Radiosurgical success or failure and the development of metastases were not statistically significantly related (Fisher's test, P Ͼ 0.05). During the follow-up period, no patient died as a result of extracranial disease.
Two patients (14%) experienced improvements in their presenting neurological symptoms, as determined in their most recent follow-up evaluations. Those patients presented with headaches, declines in visual acuity and fields, and facial numbness. Visual improvement for two patients was determined on the basis of eye chart and perimetric evaluations. One patient exhibited worsening weakness despite radiological evidence of tumor regression. Another patient, who demonstrated late recurrence at 75 months after radiosurgery, experienced neurological deterioration (including hemiparesis) and died as a result of tumor progression at 99 months after radiosurgery.
DISCUSSION
Meningeal hemangiopericytomas are known to be aggressive tumors. On the basis of imaging studies alone, they can sometimes be mistaken preoperatively for more benign meningiomas. The initial treatment for meningeal hemangiopericytomas is usually surgical resection. Early reports noted operative mortality rates that varied from 9 to 24% (6, 8, 13, 14) . These tumors may exhibit substantial intraoperative bleeding. Hemorrhage represents the most frequent cause of surgeryrelated death, as well as the greatest hindrance to tumor removal (6, 8) . Moreover, local recurrences and even extracranial metastases are not uncommon. In one series, the median time to recurrence after surgical resection was 12 months (5). Five-year metastasis rates are approximately 33% (5). Metastases have occurred 2 to 20 years after diagnosis; the average period before metastasis is 63 to 99 months (3, 6, 8, 13, 14) . Such a delay in the occurrence of metastases underscores the need for long-term follow-up monitoring.
Because meningeal hemangiopericytomas are very difficult to cure surgically, postoperative radiotherapy and radiosurgery have both been attempted. Previous experience with forms of radiation has demonstrated early dramatic shrinkage of hemangiopericytomas both inside and outside the central nervous system (3). Some have speculated that the extensive
FIGURE 1. Magnetic resonance imaging scans of a hemangiopericytoma before and after gamma knife radiosurgery. A and B, sagittal (A) and axial (B) magnetic resonance imaging scans depicting a recurrent hemangiopericytoma before gamma knife radiosurgery. C and D, similar views of the intracranial region obtained 36 months after gamma knife radiosurgery. A marked decrease in tumor size can be observed.
vascular supply of these tumors facilitates their generally favorable responses after the administration of radiation (2) .
In a recent study, external-beam radiotherapy after surgery decreased the local recurrence rate to 12.5%, compared with a rate of 88% after surgery alone (3). This finding is not universally accepted, because others demonstrated no statistically significant difference in either time to recurrence or survival duration with or without radiotherapy (19) . Radiotherapy does not seem to protect against peripheral metastasis or to increase the tumor-free interval (3). Guthrie et al. (6) and Dufour et al. (3) recommended doses of more than 5000 rad to protect against local recurrence. No adverse responses to radiation treatment of hemangiopericytomas were observed (6) . Some authors have proposed the use of preoperative radiotherapy for hemangiopericytomas, but the evidence presented is inconclusive and the approach is hindered by the difficulty of making preoperative diagnoses of hemangiopericytoma (4, 5, 9, 10, 18) .
Preoperative embolization has been reported as a means of limiting blood loss during open surgery (8, 12) . No reports of embolization as the sole treatment for a hemangiopericytoma are noted in the literature. Because of the frequent parasitization of cortical vessels, embolization of hemangiopericytomas is difficult and incomplete at best (8, 12) . Moreover, embolization is not without risks, including persistent Horner's syndrome in one case (12) . One patient in the current series underwent embolization before surgical resection. Although that patient's tumor ultimately regressed after radiosurgery, it is unclear what role, if any, embolization played in tumor regression.
A preliminary study of radiosurgery to treat recurrent hemangiopericytomas was reported by Coffey et al. (2) . Gamma knife radiosurgery was used to treat 5 patients with 11 separate tumors (7 new, 2 recurrent, and 2 residual tumors). Radiosurgery induced dramatic shrinkage of all nine tumors for which follow-up imaging data were available. One patient died as a result of neuraxis progression of his hemangiopericytomas. Two of five patients developed new intracranial tumors. Margin doses ranged from 12 to 18 Gy in that series. In that small series, the mean follow-up period was only 14.8 months.
Galanis et al. (5) reported on their experience with stereotactic radiosurgery for 10 patients with 20 separate lesions. The current series demonstrated 80% tumor control (i.e., 12 of 15 hemangiopericytomas), with a mean follow-up period of 31.3 months. These results seem comparable to those reported in previous studies of hemangiopericytomas treated with radiosurgery (2, 5, 12) . Radiosurgery seems to offer improved local tumor control for hemangiopericytomas, compared with malignant meningiomas (11, 16) . Moreover, all 12 of the tumors that responded to gamma knife radiosurgery demonstrated significant decreases in size (i.e., Ͼ50%). The mean margin dose to the hemangiopericytomas was 15 Gy, which is within the range reported in previous studies (2, 5, 12) . Ideal lesions for radiosurgical treatment are those with an average dimension of less than 3 cm, permitting the safe delivery of a therapeutic radiation dose. A radiation dose of at least 15 Gy delivered to the tumor margin seems to be recommended for hemangiopericytomas.
Three patients experienced progression of their initial tumors, 12 to 75 months after radiosurgery. The median time for recurrence in this series was 21 months. One patient experienced late tumor recurrence 75 months after radiosurgery. Before radiosurgery, that patient had undergone three resections as well as radiotherapy. After the last recurrence, the patient underwent repeat radiotherapy. Despite that treatment, the tumor progressed, and the patient died 99 months after radiosurgery. Repeat radiosurgery was performed for two patients who demonstrated local recurrence and thus experienced failure of the initial radiosurgery. Each time, repeat radiosurgery was unsuccessful in achieving lasting tumor control. Successful radiosurgery did not seem to reduce the risk of intra-or extracranial metastases. The effect of radiosurgery on the subsequent development of new metastases might be difficult to discern, because tumor cells might have metastasized before radiosurgery, particularly among patients who have experienced failure of multiple prior resections and radiotherapy. Because of their proclivity to recur and metastasize, longer-term follow-up monitoring for these rare tumors is necessary for better assessment of the efficacy of radiosurgery for local tumor control. Because of the aggressive and sometimes refractory behavior of hemangiopericytomas, multimodality treatment (i.e., radiotherapy and radiosurgery) or fractionated stereotactic radiotherapy (for larger lesions) might be necessary. Unfortunately, the rarity of these lesions likely necessitates a multi-institutional study to evaluate various treatment modalities.
With respect to neurological status after radiosurgery, one patient with an occipital lobe-based hemangiopericytoma experienced improvements in headaches, visual acuity, and visual fields. Another patient, with a parasellar lesion, experienced pronounced improvement in facial numbness. However, one patient with a parasagittal hemangiopericytoma demonstrated worsening of his preoperative hemiparesis, despite radiological imaging results indicating tumor regression. That patient's tumor was treated with 13 Gy delivered to the margin. No evidence of necrosis or infarction was observed on follow-up magnetic resonance imaging scans for that patient. However, the possibility of an adverse radiation effect cannot be excluded. Other patients who proceeded to demonstrate local recurrences or to develop extracranial metastases manifested symptoms referable to those neoplasms.
CONCLUSIONS
Hemangiopericytomas are aggressive tumors. Surgical resection is usually the initial treatment modality. However, even after resection, their high recurrence rate and their predilection for metastasis make hemangiopericytomas very challenging to manage. Treatment of these neoplasms requires a multidisciplinary approach and diligent long-term follow-up monitoring. Serial brain imaging, at approximately 6-month intervals after radiosurgery, should be performed to assess tumor responses and search for new intracranial metastases. The predilection for extracranial hemangiopericytoma metastasis to the spine and lungs warrants increased clinical attention to these regions in physical examinations and perhaps radiological screening of these regions.
Radiosurgery achieved tumor control for 80% of the lesions (12 of 15 tumors), with a mean follow-up period of 31.3 months. After radiosurgery, dramatic early shrinkage was observed for 12 hemangiopericytomas. Gamma knife radiosurgery does seem to offer at least intermediate-term tumor control for these tenacious tumors, without the necessity to perform open surgery or expose larger volumes of the brain parenchyma to high-dose, large-field radiotherapy. However, radiosurgical treatment of the primary neoplasms did not seem to confer protection from intra-or extracranial metastases. Therefore, hemangiopericytomas remain vexing neurosurgical problems.
